Belumosudil mesylate (previously SLx2119; KD025; SLx-2119; KD-025; Rezurock), the mesylate salt of belumosudil, is anorally bioavailable ROCK2 inhibitor approved in 2021 for the treatment of chronic graft versus host disease (cGvHD). It inhibits ROCK2 with an IC50 and a Ki of 60 nM and 41 nM, respectively.

纯度：≥98%

CAS：2109704-99-4